Supreme Showdown: Pharma Giants vs. Medicare Price Plans
The U.S. Supreme Court has refused to hear a challenge by major pharmaceutical companies against a plan aimed at reducing Medicare drug prices, adopted during the Biden administration. This decision supports Biden's Inflation Reduction Act to control rising drug costs, impacting drugmakers' pricing strategies and Medicare beneficiaries' expenses.
The U.S. Supreme Court has decided not to hear the pharmaceutical industry's challenge to a Biden administration plan targeting Medicare drug prices. The decision upholds lower court rulings, backing the initiative designed to control rising prescription costs under the Inflation Reduction Act of 2022.
The plan mandates negotiation of drug prices with Medicare, affecting costs for seniors and potentially altering out-of-pocket expenses and premiums. President Trump's administration supports the measure, positioning it as a strategy to address the high costs of pharmaceuticals in the U.S.
Pharmaceutical giants, including Novo Nordisk and AstraZeneca, claim the legislation infringes on their constitutional rights. Courts, however, have generally sided with the government, allowing the price negotiation efforts to proceed, impacting how drug prices are managed at a federal level.
(With inputs from agencies.)
Google News